Agnieszka Anna Gaczoł

Agnieszka Anna Gaczoł

Auto-generated profile, based on publicly available information

Agnieszka Anna Gaczoł

Gabriel Narutowicz Municipal Specialist Hospital in Kraków, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
DGDominika Grzybowska
Dominika Grzybowska
MLMaria Leśniak
Maria Leśniak
HBHubert Bednarz
Hubert Bednarz
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
AUAleksander Urbaś
Aleksander Urbaś
Introduction and aim: Depression and anxiety disorders are leading causes of disability worldwide, and many patients respond inadequately to conventional treatment. The microbiota–gut–brain axis has emerged as a candidate contributor to their pathogenesis. This review aimed to synthesise mechanistic and clinical evidence linking gut microbiota, bacterial metabolites, and vagal signalling to depression and anxiety. Material and methods: A systematic search of PubMed, Embase, and Scopus (2011–2025) was performed following PRISMA principles, using terms for the gut–brain axis, microbiota, short-chain fatty acids, tryptophan, vagus nerve, depression, and anxiety. Studies were synthesised narratively across three mechanistic pillars. Results: Patients with depression and anxiety show reduced short-chain-fatty-acid-producing taxa and enrichment of pro-inflammatory bacteria. Bacterial metabolites—short-chain fatty acids, tryptophan catabolites, and gamma-aminobutyric acid—modulate neuroinflammation, blood–brain-barrier integrity, and neurotransmission. Several anxiolytic and antidepressant-like microbial effects are abolished by vagotomy, confirming a vagal route. Randomised trials of psychobiotics show small but significant reductions in depressive symptoms. Conclusions: The gut–brain axis is a biologically plausible, therapeutically tractable contributor to mood and anxiety disorders, though heterogeneity and causal uncertainty remain.

10 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
HBHubert Bednarz
Hubert Bednarz
MMMagdalena Mortka
Magdalena Mortka
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
MKMaja Kopyto
Maja Kopyto
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
Background:Functional dyspepsia (FD) is a common disorder of gut–brain interaction and a major cause of chronic upper gastrointestinal symptoms and impaired quality of life. Current evidence challenges the traditional view of FD as solely a gastric motility disorder and indicates a multifactorial pathophysiology involving motor dysfunction, visceral hypersensitivity, duodenal immune activation, epithelial barrier impairment, gut microbiota alterations, and dysregulated gut–brain communication. Aim:To review current knowledge of the pathophysiology, clinical presentation, diagnosis, and evidence-based management of FD, with emphasis on emerging therapeutic targets and precision medicine. Material and methods:A narrative review was conducted using international clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and translational studies concerning FD diagnosis, treatment, and recent advances in disease mechanisms. Results:FD is a heterogeneous disorder in which several overlapping biological mechanisms contribute to symptom generation. Diagnosis is primarily based on the Rome IV criteria after exclusion of structural disease. Established management includes lifestyle modification, Helicobacter pylori eradication, proton pump inhibitors, prokinetics, neuromodulators, and psychological therapies. Emerging approaches targeting the duodenal microenvironment, epithelial barrier, gut microbiota, and gut–brain axis are promising. Nevertheless, treatment efficacy remains modest because of biological heterogeneity and the lack of validated biomarkers for patient stratification. Conclusions:The evolving understanding of FD supports a shift from empirical symptom-based treatment toward individualized, mechanism-informed care. Future research should focus on clinically applicable biomarkers, improved phenotyping, and high-quality clinical trials to enable precision medicine and improve long-term outcomes.

25 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZLZuzanna Lechowska
Zuzanna Lechowska
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
WKWiktoria Król
Wiktoria Król
KKKonrad Kulka
Konrad Kulka
KMKatarzyna Michta
Katarzyna Michta
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.

24 September 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
TKTomasz Kilian
Tomasz Kilian
PKPaulina Kopcińska
Paulina Kopcińska
MKMichał Kawa
Michał Kawa
KIKamil Idzik
Kamil Idzik
DGDominika Grzybowska
Dominika Grzybowska
HBHubert Bednarz
Hubert Bednarz
Combination antiretroviral therapy (ART) has transformed human immunodeficiency virus (HIV) infection from a fatal disease into a manageable chronic condition; consequently, the population of people living with HIV (PLWH) is ageing rapidly. In many high-income settings more than half of PLWH are now aged 50 years or older. To characterise the clinical and organisational challenges that arise when HIV infection and biological ageing intersect, and to summarise the emerging models of integrated HIV-geriatric care intended to address them. A narrative review of English-language literature indexed in PubMed/MEDLINE was conducted, complemented by the current guidelines of the European AIDS Clinical Society (EACS) and the World Health Organization (WHO). Search terms combined the concepts of HIV, ageing, multimorbidity, frailty, polypharmacy, neurocognitive disorders, cardiovascular disease and models of care. Landmark studies, systematic reviews, meta-analyses and large cohort studies were prioritised. Chronic immune activation and inflammation ("inflammaging"), immunosenescence, and the cumulative effects of ART and traditional risk factors drive accelerated and accentuated biological ageing in PLWH. This manifests as premature multimorbidity, an increased burden of cardiovascular disease, metabolic and bone disorders, HIV-associated neurocognitive disorder (HAND), non-AIDS-defining cancers, frailty, and geriatric syndromes. Polypharmacy and drug-drug interactions further complicate management, and traditional HIV services are poorly configured for these needs. Caring for the ageing HIV population requires a paradigm shift towards integrated, multidisciplinary and geriatric-informed models of care, systematic screening for comorbidity and frailty, structured medication review, and adoption of frameworks such as the WHO Integrated Care for Older People (ICOPE) approach. These changes should be urgently implemented in national HIV care systems, including Poland’s.

6 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MMMagdalena Mortka
Magdalena Mortka
HBHubert Bednarz
Hubert Bednarz
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
PKPaulina Kopcińska
Paulina Kopcińska
MKMaja Kopyto
Maja Kopyto
Background: Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders. Sexual dysfunction is among their most common adverse effects, impairing quality of life and treatment adherence. Increasing attention has focused on post-SSRI sexual dysfunction (PSSD), in which symptoms persist after antidepressant discontinuation. Objective: To summarize current evidence on sexual physiology, mechanisms and clinical features of antidepressant-induced sexual dysfunction (AISD) and PSSD, and available management strategies. Methods: A narrative review of English-language literature published between 2020 and 2026 was conducted using PubMed and Google Scholar. Original studies, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant case reports were included, along with essential earlier landmark publications. Results: SSRI-associated sexual dysfunction may affect desire, arousal, erection, ejaculation, orgasm, and sexual satisfaction. Prevalence estimates vary because of differences in study populations and assessment methods. Symptoms usually improve after dose reduction or discontinuation, but may persist as PSSD. Proposed mechanisms include serotonergic dysregulation, altered dopaminergic and neuroendocrine signaling, epigenetic changes, TRP ion channel dysfunction, neurotoxicity, and gut–brain axis disturbances, although none has been confirmed. Management includes dose reduction, switching to antidepressants with a lower risk of sexual adverse effects, pharmacological augmentation, and selected non-pharmacological interventions. No evidence-based treatment for PSSD has been established. Conclusions: Sexual dysfunction is a major adverse effect of SSRI therapy. Routine assessment before and during treatment may facilitate recognition and management. High-quality prospective studies are needed to clarify the epidemiology, mechanisms, and optimal treatment of PSSD.

4 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
PKPaulina Kopcińska
Paulina Kopcińska
MMMagdalena Mortka
Magdalena Mortka
HBHubert Bednarz
Hubert Bednarz
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
Background:Obesity is a chronic, multifactorial disease with rapidly growing global prevalence. Bariatric surgery remains the most effective intervention for long-term weight reduction and improvement of obesity-related comorbidities; however, 16 - 37% of patients experience inadequate weight loss or weight regain, prompting the search for less invasive pharmacological strategies. Aim:To review the efficacy and safety of GLP-1 receptor agonists in adults after bariatric surgery presenting with insufficient weight loss or weight regain. Material and methods:A narrative literature review was conducted using medical databases and current guidelines, including original and review articles in English involving adult post-bariatric patients treated with GLP-1 receptor agonists, reporting weight-related outcomes and safety data. Results:Liraglutide 3.0 mg achieved additional weight loss of approximately 5 - 6% over 6 - 8 months, with early onset of effect and comparable efficacy across surgical techniques. Once-weekly semaglutide (0.5 mg) demonstrated weight loss of 10.3% at 6 months. After 12 months of GLP-1 receptor agonist therapy (liraglutide or semaglutide combined), median total body weight loss reached 11.2%. Preliminary data on tirzepatide suggest superior efficacy: 15.5% weight loss at 6 months versus 10.3% with semaglutide after sleeve gastrectomy. Adverse events were predominantly mild to moderate gastrointestinal symptoms. Conclusions:GLP-1 receptor agonists represent a promising, less invasive option for post-bariatric weight management and should be considered before revisional surgery in appropriately selected patients. Larger randomised studies - particularly with tirzepatide - are needed to define optimal drug choice, timing, and patient selection.